Redwood Investment Management LLC Acquires New Position in United Therapeutics Corporation $UTHR

Redwood Investment Management LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, HoldingsChannel.com reports. The firm bought 2,154 shares of the biotechnology company’s stock, valued at approximately $1,167,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Torren Management LLC acquired a new position in United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. Fiduciary Financial Advisors acquired a new stake in shares of United Therapeutics during the second quarter worth $30,000. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Finally, Rakuten Securities Inc. grew its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

NASDAQ UTHR opened at $516.68 on Thursday. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The firm has a market capitalization of $22.16 billion, a P/E ratio of 18.49, a P/E/G ratio of 1.76 and a beta of 0.59. The business’s 50-day simple moving average is $531.06 and its 200-day simple moving average is $538.56.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the company earned $6.41 EPS. The company’s revenue was down 1.9% on a year-over-year basis. On average, equities research analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,631,280.08. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $511.97, for a total transaction of $4,863,715.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $166,105,082.71. The trade was a 2.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 424,075 shares of company stock valued at $227,683,710. 8.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Royal Bank Of Canada dropped their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.